Health news
The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Myfembree® (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg). The sNDA proposes to update the prescribing information to…
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linzagolix for the treatment of uterine fibroids. Linzagolix is a novel, oral gonadotropin-releasing hormone (GnRH) receptor antagonist. The NDA…
A New Drug Application (NDA) for linzagolix for the treatment of uterine fibroids has been submitted to the Food and Drug Administration. Linzagolix is a novel, oral gonadotropin-releasing hormone (GnRH) receptor antagonist. The NDA submission…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021